School of Life Sciences & Technology, Tongji University, Shanghai, 200092, China.
GeneTalks Biotech Co., Ltd, Changsha, Hunan, 410000, China.
Epigenomics. 2023 Feb;15(3):131-145. doi: 10.2217/epi-2022-0396. Epub 2023 Apr 5.
To identify DNA methylation markers for triage in a cohort of human papillomavirus-positive (HPV) women. The methylation markers were identified and evaluated for the detection of cervical high-grade squamous intraepithelial lesions (HSILs) or cervical cancer (collectively referred to as 'HSIL+') in HPV women (n = 692). Combined / methylation testing yielded HSIL+ sensitivity of 0.838 and 0.818, with a specificity of 0.827 and 0.810, in the training and test sets, respectively. For cervical cancer, the specificity and sensitivity were 0.969 and 1.000 in the training set and 0.967 and 0.875 in the test set. Moreover, the combined marker methylation test (0.86; 77/90) was more sensitive than the cytology (0.31; 28/90) for HSIL+. The combined / marker may have clinical application for detecting HSIL+ in HPV women undergoing screening.
为了在人乳头瘤病毒（HPV）阳性女性队列中确定用于分诊的 DNA 甲基化标志物。在 HPV 女性（n=692）中，鉴定了甲基化标志物并评估了其检测宫颈高级别鳞状上皮内病变（HSIL）或宫颈癌（统称为“HSIL+”）的能力。在训练集和测试集中，联合/甲基化检测的 HSIL+灵敏度分别为 0.838 和 0.818，特异性分别为 0.827 和 0.810。对于宫颈癌，训练集的特异性和灵敏度分别为 0.969 和 1.000，测试集分别为 0.967 和 0.875。此外，联合标志物甲基化检测（0.86；77/90）对于 HSIL+的敏感性高于细胞学（0.31；28/90）。联合/标志物可能具有用于在接受筛查的 HPV 女性中检测 HSIL+的临床应用。
